you attend the first study visit after joining the trial. during this visit, the study team records your medical history, measures your weight, waist size, and blood pressure, and collects blood samples to check cholesterol and other values. these measurements serve as the starting point for later comparisons.

based on a computer‑generated system, you are assigned to receive either asc30 tablets or matching placebo tablets. the assignment is double‑blind, meaning neither you nor the study staff know which one you receive.

you begin taking one tablet by mouth each day. the tablet is taken with water, at the same time each day, for a total period of 72 weeks. the exact amount of active substance is not disclosed, but the schedule is once‑daily.

you return to the study site at scheduled intervals, typically every four weeks, for the duration of the trial. at each visit, the staff measures your weight, waist circumference, and blood pressure, and may draw a small blood sample to monitor cholesterol and other safety parameters.

any symptoms or side effects you experience are recorded and reviewed to ensure safety.

you continue to take the assigned tablet each day for the full 72‑week period, unless advised otherwise by the study doctor because of safety concerns.

at the end of week 72, you attend a final study visit. the same measurements taken at baseline—weight, waist circumference, blood pressure, and blood tests—are repeated.

the primary goal of the trial is to compare the percent change in your weight from the start to week 72 between the asc30 group and the placebo group.

after the final assessments, the study medication is stopped. you may receive information about the overall study results, but no further study‑specific procedures are required.